News :: Fresh Tracks Therapeutics, Inc. (FRTX)

Contact Us

Jun 24, 2021 8:00am EDT

Brickell Biotech Announces Initiation of a Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by its Development Partner, Kaken Pharmaceutical in Japan

Jun 01, 2021 8:00am EDT

Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

May 13, 2021 4:01pm EDT

Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update

Apr 29, 2021 8:00am EDT

Brickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021

Apr 27, 2021 7:30am EDT

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Apr 23, 2021 10:01am EDT

Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary Hyperhidrosis

Apr 16, 2021 10:00am EDT

Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology’s 2021 VMX

Apr 15, 2021 8:00am EDT

Brickell Biotech Announces Publication of its HDSM-Ax Patient Reported Outcome Scale Validation Results in the Journal of Drugs in Dermatology

Mar 09, 2021 4:01pm EST

Brickell Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Mar 05, 2021 8:00am EST

Brickell Biotech To Host Key Opinion Leader Webinar on the Hyperhidrosis Market